DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 925
EU - Europa 279
AS - Asia 213
SA - Sud America 2
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.421
Nazione #
US - Stati Uniti d'America 918
PL - Polonia 105
CN - Cina 86
IT - Italia 72
SG - Singapore 72
GB - Regno Unito 26
DE - Germania 24
UA - Ucraina 20
VN - Vietnam 20
ID - Indonesia 17
TR - Turchia 17
CA - Canada 7
SE - Svezia 7
FR - Francia 5
RU - Federazione Russa 5
FI - Finlandia 4
LT - Lituania 3
BE - Belgio 2
NL - Olanda 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BO - Bolivia 1
BR - Brasile 1
EU - Europa 1
MA - Marocco 1
MK - Macedonia 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.421
Città #
Fairfield 142
Warsaw 104
Santa Clara 91
Woodbridge 84
Chandler 76
Ashburn 74
Houston 70
Singapore 62
Cambridge 46
Seattle 45
Wilmington 39
Jacksonville 25
Milan 24
Dearborn 23
Princeton 23
Dong Ket 20
Ann Arbor 18
Jakarta 17
Izmir 16
Beijing 13
San Diego 12
Ferrara 10
Nanjing 8
Shanghai 8
London 6
Nanchang 6
Hebei 5
Bremen 4
Toronto 4
Addison 3
Boardman 3
Bologna 3
Chicago 3
Helsinki 3
Jiaxing 3
Shenyang 3
Brussels 2
Calderara di Reno 2
Cesena 2
Forlimpopoli 2
Giovinazzo 2
Hefei 2
Kunming 2
Los Angeles 2
Norwalk 2
Salerno 2
Amsterdam 1
Araucária 1
Bratislava 1
Buffalo 1
Changsha 1
Changteh 1
Chongqing 1
Clifton 1
Edinburgh 1
Falls Church 1
Imola 1
Jieyang 1
Jinan 1
Jinhua 1
Kilburn 1
La Paz 1
Lanzhou 1
Leawood 1
Limeil-brévannes 1
Melito Di Napoli 1
Monterotondo 1
Mountain View 1
Munich 1
Nanyang 1
Orange 1
Ottawa 1
Phoenix 1
Piscataway 1
Portomaggiore 1
Prescot 1
Prilep 1
Redmond 1
Redwood City 1
Santa Maria Capua Vetere 1
Segrate 1
Taiyuan 1
Tianjin 1
Vicenza 1
Vienna 1
Wandsworth 1
Washington 1
Wenzhou 1
Wuhan 1
Xingtai 1
Totale 1.160
Nome #
Early use of abiraterone and radium-223 in metastatic prostate cancer 172
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 163
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 130
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 130
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 108
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 87
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 79
Testicular Microlithiasis and Testicular Germ Cell Tumours: a seven year retrospective study 67
Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide [Eur J Nucl Med Mol Imaging, DOI 10.1007/s00259-015-3042-5] 65
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer 58
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review 54
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients 52
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide 51
CAR-T cell therapy: A potential new strategy against prostate cancer 50
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 40
Targeted radioactive therapy for prostate cancer 32
Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers 31
Spotlight on PSMA as a new theranostic biomarker for bladder cancer 30
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial 29
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 29
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 29
Totale 1.486
Categoria #
all - tutte 11.491
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.491


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020147 0 0 0 0 0 0 37 33 35 19 14 9
2020/2021290 10 9 10 9 26 67 21 35 17 41 17 28
2021/2022169 13 8 4 3 4 12 18 35 8 14 15 35
2022/2023187 22 5 23 6 26 30 18 11 21 1 17 7
2023/202473 15 5 5 3 7 3 1 5 0 1 3 25
2024/2025270 13 23 55 18 69 89 3 0 0 0 0 0
Totale 1.486